Peter K. Watler is CTO at Coherus BioSciences, Inc. (CHRS). They have made 10 open-market trades across 1 company since 2015, most recently 2017-12-15.
CIK 0001512762
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CHRS | 5,900 | $6K |
Shares reported on the most recent Form 4, priced at the 2017-12-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CHRS | SELL | 2016-08-08 | 2016-08-10 | $30.00 | $1.7M | +3.5% | +2.0% | -17.3% |
| CHRS | SELL | 2016-08-08 | 2016-08-10 | $30.00 | $1.7M | +3.5% | +2.0% | -17.3% |
| CHRS | SELL | 2016-07-21 | 2016-07-25 | $26.13 | $209K | +16.7% | +20.3% | +27.6% |
| CHRS | SELL | 2016-07-21 | 2016-07-25 | $26.05 | $86K | +16.7% | +20.3% | +27.6% |
| CHRS | SELL | 2016-07-20 | 2016-07-22 | $25.02 | $1.3M | +15.1% | +24.6% | +25.3% |
| CHRS | SELL | 2016-07-20 | 2016-07-22 | $25.02 | $1.8M | +15.1% | +24.6% | +25.3% |
| CHRS | SELL | 2016-07-11 | 2016-07-13 | $20.02 | $1.7M | +5.7% | +29.3% | +25.0% |
| CHRS | SELL | 2016-05-17 | 2016-05-19 | $20.00 | $240K | -0.8% | -17.9% | +56.1% |
| CHRS | SELL | 2015-11-20 | 2016-05-04 | $27.41 | $548K | -13.5% | -2.8% | +45.3% |
| CHRS | SELL | 2015-11-20 | 2016-05-04 | $26.89 | $578K | -13.5% | -2.8% | +45.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.